Investor Relations

About Us:

InspireMD is a commercial-stage medical device company with proprietary and innovative stent designs with integrated embolic prevention systems (EPS) delivering neurovascular protection and stroke prevention. Proprietary MicroNet™ mesh addresses the primary shortcomings and harmful consequences of conventional Carotid stenting and surgery.  InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for sustained embolic protection, neurovascular protection and stroke prevention.  InspireMD is focused on changing the carotid/neurovascular market through expanding its portfolio of solutions along with pursuing applications of its MicroNet™ technology in other indications such as peripheral artery procedures.


  • Multi-billion-dollar opportunity for MicroNet™ products for multiple vascular markets worldwide
    • Advancing the conversion of invasive surgical procedures to endovascular non-invasive solutions.
    • Current stents do not adequately address the risk of post-procedural embolization.
    • Advancing and consistently positive body of evidence in clinical trial results and post-marketing, investigator-initiated studies position CGuardTMas a potential standard-of-care in treating carotid artery disease
    • Positive patient outcomes included in PARADIGM and SIBERIA studies demonstrating significant reduction in carotid stenosis/post-procedural neurologic events and silent brain infarcts, respectively.
  • Growth driven by new commercialization and expansion strategy
    • Serving 39 countries primarily through distributor channel partners with plans to go direct in largest markets.
    • Recent approval from Brazilian registration authority (ANVISA), with ongoing negotiations in Asia, including China and Japan.
    • Conditional approval from the U.S. Food and Drug Administration to initiate pivotal study of CGuard EPS for U.S. commercial launch.
    • Expanding CGuard™ users base to vascular surgeons, interventional cardiologists, and interventional neuro
    • Advancing development and launch of next generation delivery system.
  • Leadership focused on robust Go to Market sales, marketing and high-value pipeline development with an eye toward continued expansion into multiple new markets, including The United States.
  • Strategic collaboration outreach expanding for multiple MicroNet™ product applications.
  • A broad portfolio of patent-protected assets.
  • Significant focus on value inflection milestones and growth drivers.